Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
702 Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.